Literature DB >> 28230019

Application of colon interposition among the esophageal cancer patients with partial gastrectomy.

Qiuqiang Chen1, Weimin Mao2, Huanming Yu1, Yixian Liang1, Jiane Wang1, Guoping Chen3.   

Abstract

BACKGROUND: Esophageal reconstruction with colon interposition is an alternative solution for the esophageal cancer patients who have partial gastrectomy. The aim of this study was to investigate the therapeutic effects of colon interposition among the esophageal carcinoma patients with partial gastrectomy.
MATERIALS AND METHODS: Under institutional review board approval, 32 esophageal carcinoma patients with a history of partial gastrectomy were included in this study. All the patients had been diagnosed and confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma by histopathological examination. Surgical approaches, complications and therapeutic results were analyzed in the current study.
RESULTS: Thirty-two esophageal carcinoma patients (29 men, 3 women, median age 63.2 years) were included in this study. Isoperistaltic colon interposition was carried out on 14 patients; their 1-year and 2-year survival rate was 92.9% and 78.6%, respectively. Antiperistaltic colon interposition was carried out on 18 patients; their 1-year and 2-year survival rate was 88.9% and 77.8%, respectively. In which, cervical anastomotic leakage was observed on six patients.
CONCLUSION: Colon interposition is an ideal surgical approach for the esophageal carcinoma patients who had partial gastrectomy. Isoperistaltic colon interposition is preferred, but antiperistaltic colon interposition has the advantage that a longer colon can be used.

Entities:  

Mesh:

Year:  2016        PMID: 28230019     DOI: 10.4103/0973-1482.200602

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  1 in total

1.  Colonic Interposition After Adult Oesophagectomy: Systematic Review and Meta-analysis of Conduit Choice and Outcome.

Authors:  Jade Brown; Wyn G Lewis; Antonio Foliaki; Geoffrey W B Clark; Guy R J C Blackshaw; David S Y Chan
Journal:  J Gastrointest Surg       Date:  2018-03-08       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.